Compare Gold Fields Limited (GFI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gold Fields Limited vs ResMed Inc. — how do they compare? Gold Fields Limited trades at $32.32 (market cap $29.07B), while ResMed Inc. trades at $202.41 (market cap $28.80B). The key difference: Gold Fields Limited and ResMed Inc. are close in size by market cap, and Gold Fields Limited pays the higher dividend (7.03%). Which is the better fit depends on your goals.
| GFI | RMD | |
|---|---|---|
Market Cap | $29.07B | $28.80B |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $293.73 |
52-Week Low | $23.95 | $182.82 |
Enterprise Value | $30.51B | $27.99B |
Dividend Yield | 7.03% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $33.33, down 0.6% with a bearish technical signal despite strong fundamental metrics including a P/E of 8.37, net income margin of 40.76%, and ROE of 52.33%. Recent earnings show mixed results with a Q1 2025 beat but subsequent misses. The company demonstrates robust cash flow growth with 2025 operating cash flow projected at $3.8B, while technical indicators show oversold conditions with RSI at 26.87.
GFI presents a compelling value opportunity with attractive valuation multiples and exceptional profitability metrics, though recent earnings misses and bearish technical momentum create near-term uncertainty. The 57% upside to the $52.75 consensus price target suggests significant potential, but investors should monitor operational execution and gold price volatility as key risk factors.
ResMed (RMD) trades at $196.37, up 1.74% with strong fundamental performance including 27.44% net margins and consistent earnings beats. The company recently sold its MatrixCare business for $490 million to sharpen focus on core sleep and respiratory care markets. Technical indicators show bearish momentum despite oversold RSI conditions, while fundamentals demonstrate robust revenue growth from $5.15B to projected $5.5B in 2026.
RMD presents a compelling growth story with 40% analyst buy ratings and $245.88 consensus target suggesting 25% upside. Key risks include competitive pressures in medical technology and execution of strategic refocusing. The stock's current valuation at 19.15 P/E appears reasonable given earnings momentum and market leadership in sleep apnea treatment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
